-
1
-
-
77956401725
-
Equipoise lost: Ethics, costs, and the regulation of cancer clinical research
-
Stewart, D. J., Whitney, S. N. & Kurzrock, R. Equipoise lost: Ethics, costs, and the regulation of cancer clinical research. J. Clin. Oncol. 28, 2925-2935 (2010
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 2925-2935
-
-
Stewart, D.J.1
Whitney, S.N.2
Kurzrock, R.3
-
2
-
-
57649109461
-
Clinical research for rare disease: Opportunities, challenges, and solutions
-
Griggs, R. C. et al. Clinical research for rare disease: Opportunities, challenges, and solutions. Mol. Genet. Metab. 96, 20-26 (2009
-
(2009)
Mol. Genet. Metab
, vol.96
, pp. 20-26
-
-
Griggs, R.C.1
-
3
-
-
84868203763
-
-
eds Mehta A. Beck M. & Sunder-Plassmann G.) Ch. 11 Oxford PharmaGenesis, Oxford
-
Shah, R. R. in Fabry Disease: perspectives from 5 Years of FOS (eds Mehta, A., Beck, M. & Sunder-Plassmann, G.) Ch. 11 (Oxford PharmaGenesis, Oxford, 2006
-
(2006)
Fabry Disease: perspectives From 5 Years Of FOS
-
-
Shah, R.R.1
-
5
-
-
56749132011
-
Heterogeneity in cancer guidelines: Should we eradicate or tolerate
-
Orphan Drug Act No 97- 414 PubL 1983
-
Pentheroudakis, G. et al. Heterogeneity in cancer guidelines: Should we eradicate or tolerate? Ann. Oncol. 19, 2067-2078 (2008 Orphan Drug Act. No. 97-414 Pub. L (1983
-
(2008)
Ann Oncol
, vol.19
, pp. 2067-2078
-
-
Pentheroudakis, G.1
-
7
-
-
80755140638
-
Rare cancers are not so rare: The rare cancer burden in Europe
-
Gatta, G. et al. Rare cancers are not so rare: The rare cancer burden in Europe. Eur. J. Cancer 47, 2493-2511 (2011
-
(2011)
Eur. J. Cancer
, vol.47
, pp. 2493-2511
-
-
Gatta, G.1
-
10
-
-
55049089102
-
Prevalence of zebras in general practice: Data from the Continuous Morbidity Registration Nijmegen
-
Van De Laar F. A., Bor, H. & van de Lisdonk, E. H. Prevalence of zebras in general practice: Data from the Continuous Morbidity Registration Nijmegen. Eur. J. Gen. Pract. 14 (Suppl. 1), 44-46 (2008
-
(2008)
Eur J. Gen. Pract
, vol.14
, Issue.SUPPL. 1
, pp. 44-46
-
-
Van De Laar, F.A.1
Bor, H.2
Van De Lisdonk, E.H.3
-
11
-
-
15544389968
-
What is targeted therapy
-
Sledge, G. W. Jr. What is targeted therapy? J. Clin. Oncol. 23, 1614-1615 (2005
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 1614-1615
-
-
Sledge Jr., G.W.1
-
12
-
-
84863897798
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial
-
Van Cutsem, E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 30, 2119-2127 (2012
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 2119-2127
-
-
Van Cutsem, E.1
-
13
-
-
84862859820
-
Safety, activity, and immune correlates of anti PD 1 antibody in cancer
-
Topalian, S. L. et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
-
14
-
-
80054989315
-
Trastuzumab emtansine (T DM1): A novel agent for targeting HER2+ breast cancer
-
Burris, H. A. 3rd, Tibbitts, J., Holden, S. N. & Lewis Phillips, G. D. Trastuzumab emtansine (T DM1): A novel agent for targeting HER2+ breast cancer. Clin. Breast Cancer 11, 275-282 (2011
-
(2011)
Clin. Breast Cancer
, vol.11
, pp. 275-282
-
-
Burris III, H.A.1
Tibbitts, J.2
Holden, S.N.3
Lewis Phillips, G.D.4
-
15
-
-
34248204234
-
Uncommon tumors and exceptional therapies: Paradox or paradigm
-
Braiteh, F. & Kurzrock, R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol. Cancer Ther. 6, 1175-1179 (2007
-
(2007)
Mol. Cancer Ther
, vol.6
, pp. 1175-1179
-
-
Braiteh, F.1
Kurzrock, R.2
-
16
-
-
83455176258
-
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma
-
Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817 (2011
-
(2011)
Cancer Cell
, vol.20
, pp. 810-817
-
-
Snuderl, M.1
-
17
-
-
84863393080
-
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
-
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 883-892
-
-
Gerlinger, M.1
-
18
-
-
84862526929
-
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
-
Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012
-
(2012)
Nature
, vol.486
, pp. 395-399
-
-
Shah, S.P.1
-
19
-
-
78049426513
-
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
-
Choi, Y. L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010
-
(2010)
N. Engl. J. Med
, vol.363
, pp. 1734-1739
-
-
Choi, Y.L.1
-
20
-
-
79960127513
-
Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer
-
Moulder, S. et al. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer. J. Clin. Oncol. 29, e572-e575 (2011
-
(2011)
J. Clin. Oncol
, vol.29
-
-
Moulder, S.1
-
21
-
-
0028227312
-
Treatment of patients with hairy cell leukemia with 2 chloro 2'-deoxyadenosine (2-CdA
-
Robak, T., Krykowski, E., Blasinska-Morawiec, M. & Urbanska-Rys, H. Treatment of patients with hairy cell leukemia with 2 chloro 2'-deoxyadenosine (2-CdA). Arch. Immunol. Ther. Exp. (Warsz) 42, 25-29 (1994
-
(1994)
Arch. Immunol. Ther. Exp. (Warsz)
, vol.42
, pp. 25-29
-
-
Robak, T.1
Krykowski, E.2
Blasinska-Morawiec, M.3
Urbanska-Rys, H.4
-
22
-
-
0037103424
-
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
-
Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002
-
(2002)
N. Engl. J. Med
, vol.347
, pp. 472-480
-
-
Demetri, G.D.1
-
23
-
-
23944489636
-
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
-
Giagounidis, A. A. et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann. Hematol. 84, 569-571 (2005
-
(2005)
Ann. Hematol
, vol.84
, pp. 569-571
-
-
Giagounidis, A.A.1
-
24
-
-
0027484628
-
Multi-institutional study of all trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia
-
Leukaemia Study Group of the Ministry of Health and Welfare
-
Ohno, R. et al. Leukaemia Study Group of the Ministry of Health and Welfare. Multi-institutional study of all trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 7, 1722-1727 (1993
-
(1993)
Leukemia
, vol.7
, pp. 1722-1727
-
-
Ohno, R.1
-
25
-
-
84864446464
-
How I treat CML blast crisis
-
Hehlmann, R. How I treat CML blast crisis. Blood 120, 737-747 (2012
-
(2012)
Blood
, vol.120
, pp. 737-747
-
-
Hehlmann, R.1
-
26
-
-
84861839077
-
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
-
Huang, X., Cortes, J. & Kantarjian, H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118, 3123-3127 (2012
-
(2012)
Cancer
, vol.118
, pp. 3123-3127
-
-
Huang, X.1
Cortes, J.2
Kantarjian, H.3
-
27
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001
-
(2001)
N. Engl. J. Med
, vol.344
, pp. 1038-1042
-
-
Druker, B.J.1
-
28
-
-
84860571418
-
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure
-
Cornelison, A. M., Kantarjian, H., Cortes, J. & Jabbour, E. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin. Lymphoma Myeloma Leuk. 11 (Suppl. 1), S101-S110 (2011
-
(2011)
Clin. Lymphoma Myeloma Leuk
, vol.11
, Issue.SUPPL. 1
-
-
Cornelison, A.M.1
Kantarjian, H.2
Cortes, J.3
Jabbour, E.4
-
29
-
-
84861663006
-
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: Detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood
-
Razga, F. et al. Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: Detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood. Mol. Diagn. Ther. 16, 163-166 (2012
-
(2012)
Mol. Diagn. Ther
, vol.16
, pp. 163-166
-
-
Razga, F.1
-
30
-
-
84859478963
-
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain
-
Levinson, N. M. & Boxer, S. G. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS ONE 7, e29828 (2012
-
(2012)
PLoS ONE
, vol.7
-
-
Levinson, N.M.1
Boxer, S.G.2
-
31
-
-
74549122017
-
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance
-
Azam, M. et al. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem. Biol. Drug Des. 75, 223-227 (2010
-
(2010)
Chem. Biol. Drug Des
, vol.75
, pp. 223-227
-
-
Azam, M.1
-
32
-
-
84863393301
-
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis
-
Cassier, P. A. et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 118, 1649-1655 (2012
-
(2012)
Cancer
, vol.118
, pp. 1649-1655
-
-
Cassier, P.A.1
-
33
-
-
79955645165
-
Dermatofibrosarcoma protuberans-derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib
-
Stacchiotti, S. et al. Dermatofibrosarcoma protuberans-derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib. Int. J. Cancer 129, 1761-1772 (2011
-
(2011)
Int. J. Cancer
, vol.129
, pp. 1761-1772
-
-
Stacchiotti, S.1
-
34
-
-
84863356975
-
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine fullblown leukemia
-
Zhao, L. J. et al. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine fullblown leukemia. Blood 119, 2873-2882 (2012
-
(2012)
Blood
, vol.119
, pp. 2873-2882
-
-
Zhao, L.J.1
-
35
-
-
76949088438
-
Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia
-
Nacheva, E. P. et al. Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. BMC Genomics 11, 41 (2010
-
(2010)
BMC Genomics
, vol.11
, Issue.41
-
-
Nacheva, E.P.1
-
36
-
-
84861813715
-
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia
-
Beekman, R. et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 119, 5071-5077 (2012
-
(2012)
Blood
, vol.119
, pp. 5071-5077
-
-
Beekman, R.1
-
37
-
-
42149100512
-
Primary extramedullary plasmacytoma: Similarities with and differences from multiple myeloma revealed by interphase cytogenetics
-
Bink, K. et al. Primary extramedullary plasmacytoma: Similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica 93, 623-626 (2008
-
(2008)
Haematologica
, vol.93
, pp. 623-626
-
-
Bink, K.1
-
38
-
-
67649329200
-
P53 nuclear accumulation is associated with extramedullary progression of multiple myeloma
-
Sheth, N., Yeung, J. & Chang, H. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk. Res. 33, 1357-1360 (2009
-
(2009)
Leuk. Res
, vol.33
, pp. 1357-1360
-
-
Sheth, N.1
Yeung, J.2
Chang, H.3
-
39
-
-
49249114037
-
Preceding orbital granulocytic sarcoma in an adult patient with acute myelogenous leukemia with t(8;21): A case study and review of the literature
-
Lee, S. G. et al. Preceding orbital granulocytic sarcoma in an adult patient with acute myelogenous leukemia with t(8;21): A case study and review of the literature. Cancer Genet. Cytogenet. 185, 51-54 (2008
-
(2008)
Cancer Genet. Cytogenet
, vol.185
, pp. 51-54
-
-
Lee, S.G.1
-
40
-
-
84863581473
-
Myeloma as a model for the process of metastasis: Implications for therapy
-
Ghobrial, I. M. Myeloma as a model for the process of metastasis: Implications for therapy. Blood 120, 20-30 (2012
-
(2012)
Blood
, vol.120
, pp. 20-30
-
-
Ghobrial, I.M.1
-
41
-
-
41949111045
-
Acute promyelocytic leukemia: From highly fatal to highly curable
-
Wang, Z. Y. & Chen, Z. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111, 2505-2515 (2008
-
(2008)
Blood
, vol.111
, pp. 2505-2515
-
-
Wang, Z.Y.1
Chen, Z.2
-
42
-
-
80055023000
-
Advances in therapies for acute promyelocytic leukemia
-
Kamimura, T., Miyamoto, T., Harada, M. & Akashi, K. Advances in therapies for acute promyelocytic leukemia. Cancer Sci. 102, 1929-1937 (2011
-
(2011)
Cancer Sci
, vol.102
, pp. 1929-1937
-
-
Kamimura, T.1
Miyamoto, T.2
Harada, M.3
Akashi, K.4
-
43
-
-
62549083523
-
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia
-
Hu, J. et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 106, 3342-3347 (2009
-
(2009)
Proc. Natl Acad. Sci. USA
, vol.106
, pp. 3342-3347
-
-
Hu, J.1
-
44
-
-
34548006143
-
Localized mediastinal lymph node hyperplasia resembling thymoma
-
Castleman, B., Iverson, L. & Menendez, V. P. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 9, 822-830 (1956
-
(1956)
Cancer
, vol.9
, pp. 822-830
-
-
Castleman, B.1
Iverson, L.2
Menendez, V.P.3
-
45
-
-
68849122422
-
Castleman disease: An update on classification and the spectrum of associated lesions
-
Cronin, D. M. & Warnke, R. A. Castleman disease: An update on classification and the spectrum of associated lesions. Adv. Anat. Pathol. 16, 236-246 (2009
-
(2009)
Adv. Anat. Pathol
, vol.16
, pp. 236-246
-
-
Cronin, D.M.1
Warnke, R.A.2
-
46
-
-
0029069445
-
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity based lymphomas
-
Cesarman, E., Chang, Y., Moore, P. S. & Knowles, D. M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity based lymphomas. N. Engl. J. Med. 332, 1186-1191 (1995
-
(1995)
N. Engl. J. Med
, vol.332
, pp. 1186-1191
-
-
Cesarman, E.1
Chang, Y.2
Moore, P.S.3
Knowles, D.M.4
-
47
-
-
0031060368
-
Human herpesvirus 8 encodes a homolog of interleukin 6
-
Neipel, F. et al. Human herpesvirus 8 encodes a homolog of interleukin 6. J. Virol. 71, 839-842 (1997
-
(1997)
J. Virol
, Issue.71
, pp. 839-842
-
-
Neipel, F.1
-
48
-
-
0024540981
-
Giant lymph node hyperplasia (Castleman's disease) with spontaneous production of high levels of B cell differentiation factor activity
-
Yabuhara, A. et al. Giant lymph node hyperplasia (Castleman's disease) with spontaneous production of high levels of B cell differentiation factor activity. Cancer 63, 260-265 (1989
-
(1989)
Cancer
, vol.63
, pp. 260-265
-
-
Yabuhara, A.1
-
49
-
-
0028013066
-
Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti interleukin 6 antibody
-
Beck, J. T. et al. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti interleukin 6 antibody. N. Engl. J. Med. 330, 602-605 (1994
-
(1994)
N. Engl. J. Med
, vol.330
, pp. 602-605
-
-
Beck, J.T.1
-
50
-
-
58149154996
-
Mechanisms and pathologic significances in increase in serum interleukin 6 (IL 6) and soluble IL 6 receptor after administration of an anti IL 6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
-
Nishimoto, N. et al. Mechanisms and pathologic significances in increase in serum interleukin 6 (IL 6) and soluble IL 6 receptor after administration of an anti IL 6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959-3964 (2008
-
(2008)
Blood
, vol.112
, pp. 3959-3964
-
-
Nishimoto, N.1
-
51
-
-
77957283115
-
Siltuximab, a novel anti -interleukin 6 monoclonal antibody, for Castleman's disease
-
Van Rhee, F. et al. Siltuximab, a novel anti -interleukin 6 monoclonal antibody, for Castleman's disease. J. Clin. Oncol. 28, 3701-3708 (2010
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 3701-3708
-
-
Van Rhee, F.1
-
52
-
-
34748822990
-
Cutaneous castleman's disease responds to anti interleukin 6 treatment
-
Ahmed, B. et al. Cutaneous castleman's disease responds to anti interleukin 6 treatment. Mol. Cancer Ther. 6, 2386-2390 (2007
-
(2007)
Mol. Cancer Ther
, vol.6
, pp. 2386-2390
-
-
Ahmed, B.1
-
53
-
-
77953441380
-
Successful treatment of Castleman's disease with interleukin 1 receptor antagonist (Anakinra
-
El-Osta, H., Janku, F. & Kurzrock, R. Successful treatment of Castleman's disease with interleukin 1 receptor antagonist (Anakinra). Mol. Cancer Ther. 9, 1485-1488 (2010
-
(2010)
Mol. Cancer Ther
, vol.9
, pp. 1485-1488
-
-
El-Osta, H.1
Janku, F.2
Kurzrock, R.3
-
54
-
-
79955556128
-
Castleman's disease: From basic mechanisms to molecular therapeutics
-
El-Osta, H. E. & Kurzrock, R. Castleman's disease: From basic mechanisms to molecular therapeutics. Oncologist 16, 497-511 (2011
-
(2011)
Oncologist
, vol.16
, pp. 497-511
-
-
El-Osta, H.E.1
Kurzrock, R.2
-
55
-
-
79251534679
-
Ewing sarcoma: An eponym window to history
-
2011
-
Cripe, T. P. Ewing sarcoma: An eponym window to history. Sarcoma 2011, 457532 (2011
-
(2011)
Sarcoma
, pp. 457532
-
-
Cripe, T.P.1
-
56
-
-
36048961176
-
Clinical relevance of molecular genetics to paediatric sarcomas
-
Slater, O. & Shipley, J. Clinical relevance of molecular genetics to paediatric sarcomas. J. Clin. Pathol. 60, 1187-1194 (2007
-
(2007)
J. Clin. Pathol
, vol.60
, pp. 1187-1194
-
-
Slater, O.1
Shipley, J.2
-
58
-
-
0029586973
-
Childhood cancer in Britain: The national registry of childhood tumours and incidence rates 1978-1987
-
Stiller, C. A., Allen, M. B. & Eatock, E. M. Childhood Cancer in Britain: The National Registry of Childhood Tumours and Incidence Rates 1978-1987. Eur. J. Cancer 31A, 2028-2034 (1995
-
(1995)
Eur. J. Cancer 31A
, pp. 2028-2034
-
-
Stiller, C.A.1
Allen, M.B.2
Eatock, E.M.3
-
60
-
-
80053994190
-
R1507, an anti insulin like growth factor 1 receptor (IGF-1R) antibody, and EWS/FLI 1 si RNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt axis
-
Huang, H. J. et al. R1507, an anti insulin like growth factor 1 receptor (IGF-1R) antibody, and EWS/FLI 1 siRNA in Ewing's sarcoma: Convergence at the IGF/IGFR/Akt axis. PLoS ONE 6, e26060 (2011
-
(2011)
PLoS ONE
, vol.6
-
-
Huang, H.J.1
-
61
-
-
77950974697
-
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor I receptor antagonist, in patients with advanced solid tumors
-
Kurzrock, R. et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor I receptor antagonist, in patients with advanced solid tumors. Clin. Cancer Res. 16, 2458-2465 (2010
-
(2010)
Clin. Cancer Res
, vol.16
, pp. 2458-2465
-
-
Kurzrock, R.1
-
62
-
-
73349099049
-
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
-
Tolcher, A. W. et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27, 5800-5807 (2009
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 5800-5807
-
-
Tolcher, A.W.1
-
63
-
-
80052831572
-
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer
-
Naing, A. et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin. Cancer Res. 17, 6052-6060 (2011
-
(2011)
Clin. Cancer Res
, vol.17
, pp. 6052-6060
-
-
Naing, A.1
-
64
-
-
79953742425
-
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: Response/resistance signatures
-
Subbiah, V. et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: Response/resistance signatures. PLoS ONE 6, e18424 (2011
-
(2011)
PLoS ONE
, vol.6
-
-
Subbiah, V.1
-
65
-
-
84855182612
-
Diabetes and cancer: Is diabetes causally related to cancer
-
Suh, S. & Kim, K. W. Diabetes and cancer: Is diabetes causally related to cancer? Diabetes Metab. J. 35, 193-198 (2011
-
(2011)
Diabetes Metab. J.
, vol.35
, pp. 193-198
-
-
Suh, S.1
Kim, K.W.2
-
66
-
-
84855268036
-
Imatinib mesylate: Past successes and future challenges in the treatment of gastrointestinal stromal tumors
-
Ksienski, D. Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors. Clin. Med. Insights Oncol. 5, 365-379 (2011
-
(2011)
Clin. Med. Insights Oncol
, vol.5
, pp. 365-379
-
-
Ksienski, D.1
-
67
-
-
84861759106
-
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of Radiation Therapy Oncology Group 0132
-
Wang, D. et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann. Surg. Oncol. 19, 1074-1080 (2012
-
(2012)
Ann. Surg. Oncol
, vol.19
, pp. 1074-1080
-
-
Wang, D.1
-
68
-
-
84859187987
-
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial
-
Joensuu, H. et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 307, 1265-1272 (2012
-
(2012)
JAMA
, vol.307
, pp. 1265-1272
-
-
Joensuu, H.1
-
69
-
-
84858179982
-
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors (GIST
-
Miranda, C. et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors (GIST). Clin. Cancer Res. 18, 1769-1776 (2012
-
(2012)
Clin. Cancer Res
, vol.18
, pp. 1769-1776
-
-
Miranda, C.1
-
70
-
-
73949094832
-
BRAF mutation status in gastrointestinal stromal tumors
-
Hostein, I. et al. BRAF mutation status in gastrointestinal stromal tumors. Am. J. Clin. Pathol. 133, 141-148 (2010
-
(2010)
Am. J. Clin. Pathol
, vol.133
, pp. 141-148
-
-
Hostein, I.1
-
71
-
-
0037225829
-
Imatinib mesylate: In the treatment of gastrointestinal stromal tumours
-
Croom, K. F. & Perry, C. M. Imatinib mesylate: In the treatment of gastrointestinal stromal tumours. Drugs 63, 513-522 (2003
-
(2003)
Drugs
, vol.63
, pp. 513-522
-
-
Croom, K.F.1
Perry, C.M.2
-
72
-
-
79957500033
-
A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST
-
Blay, J. Y. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Cancer Treat. Rev. 37, 373-384 (2011
-
(2011)
Cancer Treat. Rev
, vol.37
, pp. 373-384
-
-
Blay, J.Y.1
-
73
-
-
80155151884
-
Vemurafenib
-
Flaherty, K. T., Yasothan, U. & Kirkpatrick, P. Vemurafenib. Nat. Rev. Drug Discov. 10, 811-812 (2011
-
(2011)
Nat. Rev. Drug Discov
, vol.10
, pp. 811-812
-
-
Flaherty, K.T.1
Yasothan, U.2
Kirkpatrick, P.3
-
74
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011
-
(2011)
N. Engl. J. Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
-
75
-
-
66249087984
-
Cancer: Melanoma troops massed
-
Huang, P. & Marais, R. Cancer: Melanoma troops massed. Nature 459, 336-337 (2009
-
(2009)
Nature
, vol.459
, pp. 336-337
-
-
Huang, P.1
Marais, R.2
-
76
-
-
84855472280
-
Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma
-
Luke, J. J. & Hodi, F. S. Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma. Clin. Cancer Res. 18, 9-14 (2012
-
(2012)
Clin. Cancer Res
, vol.18
, pp. 9-14
-
-
Luke, J.J.1
Hodi, F.S.2
-
77
-
-
27844567142
-
Distinct sets of genetic alterations in melanoma
-
Curtin, J. A. et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147 (2005
-
(2005)
N. Engl. J. Med
, vol.353
, pp. 2135-2147
-
-
Curtin, J.A.1
-
78
-
-
80052782508
-
Molecular analysis of thyroid tumors
-
Bhaijee, F. & Nikiforov, Y. E. Molecular analysis of thyroid tumors. Endocr. Pathol. 22, 126-133 (2011
-
(2011)
Endocr. Pathol
, vol.22
, pp. 126-133
-
-
Bhaijee, F.1
Nikiforov, Y.E.2
-
79
-
-
84857076207
-
Quantitative cell-free DNA KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan
-
Spindler, K. L., Pallisgaard, N., Vogelius, I. & Jakobsen, A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin. Cancer Res. 18, 1177-1185 (2012
-
(2012)
Clin. Cancer Res
, vol.18
, pp. 1177-1185
-
-
Spindler, K.L.1
Pallisgaard, N.2
Vogelius, I.3
Jakobsen, A.4
-
80
-
-
79959293462
-
BRAF mutations in hairy-cell leukemia
-
Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011
-
(2011)
N. Engl. J. Med
, vol.364
, pp. 2305-2315
-
-
Tiacci, E.1
-
81
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
-
82
-
-
84861417677
-
BRAF inhibition in refractory hairy-cell leukemia
-
Dietrich, S. et al. BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366, 2038-2040 (2012
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 2038-2040
-
-
Dietrich, S.1
-
83
-
-
80054111050
-
CD30-targeted antibody therapy
-
Younes, A. CD30-targeted antibody therapy. Curr. Opin. Oncol. 23, 587-593 (2011
-
(2011)
Curr. Opin. Oncol
, vol.23
, pp. 587-593
-
-
Younes, A.1
-
84
-
-
84863678237
-
Brentuximab vedotin (SGN 35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study
-
Pro, B. et al. Brentuximab vedotin (SGN 35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J. Clin. Oncol. 30, 2190-2196 (2012
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 2190-2196
-
-
Pro, B.1
-
85
-
-
79953830127
-
Brentuximab vedotin for the treatment of CD30+ lymphomas
-
Foyil, K. V. & Bartlett, N. L. Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy 3, 475-485 (2011
-
(2011)
Immunotherapy
, vol.3
, pp. 475-485
-
-
Foyil, K.V.1
Bartlett, N.L.2
-
86
-
-
84855391703
-
Brentuximab vedotin
-
Younes, A., Yasothan, U. & Kirkpatrick, P. Brentuximab vedotin. Nat. Rev. Drug Discov. 11, 19-20 (2012
-
(2012)
Nat. Rev. Drug Discov
, vol.11
, pp. 19-20
-
-
Younes, A.1
Yasothan, U.2
Kirkpatrick, P.3
-
87
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
-
Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290, 2149-2158 (2003
-
(2003)
JAMA
, vol.290
, pp. 2149-2158
-
-
Kris, M.G.1
-
88
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer
-
Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537 (2005
-
(2005)
Lancet
, vol.366
, pp. 1527-1537
-
-
Thatcher, N.1
-
89
-
-
20244389188
-
Predictive and prognostic impact of epidermal growth factor receptor mutation in non small cell lung cancer patients treated with gefitinib
-
Han, S. W. et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non small cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23, 2493-2501 (2005
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 2493-2501
-
-
Han, S.W.1
-
90
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib
-
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004
-
(2004)
N. Engl. J. Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
-
91
-
-
84876703546
-
-
ASCO. ASCO's Blueprint for Transforming Clinical and Translational Cancer Research
-
ASCO. ASCO's Blueprint for Transforming Clinical and Translational Cancer Research. Cancer in the Molecular Era: Identifying the Drivers of Lung Cancer [online], http://www.asco.org/ascov2/department%20content/ cancer%20policy%20and%20clinical%20affairs/downloads/blueprint.pdf (2012
-
(2012)
Cancer in the Molecular Era: Identifying the Drivers of Lung Cancer [online]
-
-
-
92
-
-
84856893071
-
Anaplastic lymphoma kinase as a new target for the treatment of non small cell lung cancer
-
Tiseo, M. et al. Anaplastic lymphoma kinase as a new target for the treatment of non small cell lung cancer. Expert Rev. Anticancer Ther. 11, 1677-1687 (2011
-
(2011)
Expert Rev. Anticancer Ther
, vol.11
, pp. 1677-1687
-
-
Tiseo, M.1
-
93
-
-
84863943675
-
Crizotinib for ALK-rearranged non-small cell lung cancer: A new targeted therapy for a new target
-
Gandhi, L. & Jänne, P. A. Crizotinib for ALK-rearranged non-small cell lung cancer: A new targeted therapy for a new target. Clin. Cancer Res. 18, 3737-3742 (2012
-
(2012)
Clin. Cancer Res
, vol.18
, pp. 3737-3742
-
-
Gandhi, L.1
Jänne, P.A.2
-
94
-
-
70449378917
-
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: How does it relate to the original lenalidomide experience in MDS
-
Kantarjian, H et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: How does it relate to the original lenalidomide experience in MDS? Cancer 115, 5202-5209 (2009
-
(2009)
Cancer
, vol.115
, pp. 5202-5209
-
-
Kantarjian, H.1
-
95
-
-
79956088970
-
Myelodysplastic syndromes: Update on diagnosis, risk-stratification, and management
-
Garcia-Manero, G. Myelodysplastic syndromes: Update on diagnosis, risk-stratification, and management. Am. J. Hematol. 86, 490-498 (2011
-
(2011)
Am. J. Hematol
, vol.86
, pp. 490-498
-
-
Garcia-Manero, G.1
-
96
-
-
76649129531
-
Lenalidomide in myelodysplastic syndromes: An erythropoiesis-stimulating agent or more
-
Komrokji, R. S., Lancet, J. E. & List, A. F. Lenalidomide in myelodysplastic syndromes: An erythropoiesis-stimulating agent or more? Curr. Hematol. Malig. Rep. 5, 9-14 (2010
-
(2010)
Curr Hematol. Malig. Rep
, vol.5
, pp. 9-14
-
-
Komrokji, R.S.1
Lancet, J.E.2
List, A.F.3
-
97
-
-
77958050048
-
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
-
Heise, C., Carter, T., Schafer, P. & Chopra, R. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev. Anticancer Ther. 10, 1663-1672 (2010
-
(2010)
Expert Rev. Anticancer Ther
, vol.10
, pp. 1663-1672
-
-
Heise, C.1
Carter, T.2
Schafer, P.3
Chopra, R.4
-
98
-
-
80053621748
-
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate 1 risk myelodysplastic syndromes with del5q
-
Fenaux, P. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate 1 risk myelodysplastic syndromes with del5q. Blood 118, 3765-3776 (2011
-
(2011)
Blood
, vol.118
, pp. 3765-3776
-
-
Fenaux, P.1
-
99
-
-
33750390130
-
The challenges of Proteus syndrome: Diagnosis and management
-
Biesecker, L. The challenges of Proteus syndrome: Diagnosis and management. Eur. J. Hum. Genet. 14, 1151-1157 (2006
-
(2006)
Eur. J. Hum. Genet
, vol.14
, pp. 1151-1157
-
-
Biesecker, L.1
-
100
-
-
84860389181
-
A mosaic activating mutation in AKT1 associated with the Proteus syndrome
-
Lindhurst, M. J. et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med. 365, 611-619 (2011
-
(2011)
N. Engl. J. Med
, vol.365
, pp. 611-619
-
-
Lindhurst, M.J.1
-
101
-
-
79955045309
-
Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment
-
Piha-Paul, S. A., Hong, D. S. & Kurzrock, R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. J. Clin. Oncol. 29, e333-e335 (2011
-
(2011)
J. Clin. Oncol
, vol.29
-
-
Piha-Paul, S.A.1
Hong, D.S.2
Kurzrock, R.3
-
103
-
-
84655175698
-
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial
-
Wells, S. A. Jr et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134-141 (2012
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 134-141
-
-
Wells Jr., S.A.1
-
104
-
-
79959936054
-
Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
-
Kurzrock, R. et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29, 2660-2666 (2011
-
(2011)
J. Clin. Oncol
, vol.29
, pp. 2660-2666
-
-
Kurzrock, R.1
-
105
-
-
84855350870
-
Effectiveness of adaptive designs for phase II cancer trials
-
López, M. F., Dupuy, J. F. & Gonzalez, C. V. Effectiveness of adaptive designs for phase II cancer trials. Contemp. Clin. Trials 33, 223-227 (2012
-
(2012)
Contemp. Clin. Trials
, vol.33
, pp. 223-227
-
-
López, M.F.1
Dupuy, J.F.2
Gonzalez, C.V.3
-
106
-
-
55549126273
-
Anaplastic large-cell lymphoma in women with breast implants
-
de Jong, D. et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 300, 2030-2035 (2008
-
(2008)
JAMA
, vol.300
, pp. 2030-2035
-
-
De Jong, D.1
-
107
-
-
79951976403
-
Crizotinib in anaplastic large-cell lymphoma
-
Gambacorti-Passerini, C., Messa, C. & Pogliani, E. M. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 364, 775-776 (2011
-
(2011)
N. Engl. J. Med
, vol.364
, pp. 775-776
-
-
Gambacorti-Passerini, C.1
Messa, C.2
Pogliani, E.M.3
-
108
-
-
67449101269
-
Thoracic manifestations of Castleman's disease [French]
-
Dégot, T., Métivier, A. C., Casnedi, S., Chenard, M. P. & Kessler, R. Thoracic manifestations of Castleman's disease [French]. Rev. Pneumol. Clin. 65, 101-107 (2009
-
(2009)
Rev. Pneumol. Clin
, vol.65
, pp. 101-107
-
-
Dégot, T.1
Métivier, A.C.2
Casnedi, S.3
Chenard, M.P.4
Kessler, R.5
-
109
-
-
52049126174
-
Chemoprevention and treatment of experimental Cowden's disease By MTOR inhibition with rapamycin
-
Squarize, C. H., Castilho, R. M. & Gutkind, J. S. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res. 68, 7066-7072 (2008
-
(2008)
Cancer Res
, vol.68
, pp. 7066-7072
-
-
Squarize, C.H.1
Castilho, R.M.2
Gutkind, J.S.3
-
110
-
-
80051802494
-
Dermatofibrosarcoma protuberans: A clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors
-
Llombart, B. et al. Dermatofibrosarcoma protuberans: A clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J. Am. Acad. Dermatol. 65, 564-575 (2011
-
(2011)
J. Am. Acad. Dermatol
, vol.65
, pp. 564-575
-
-
Llombart, B.1
-
111
-
-
77957342344
-
Immunotoxins: A promising treatment modality for metastatic melanoma
-
Risberg, K., Fodstad, O. & Andersson, Y. Immunotoxins: A promising treatment modality for metastatic melanoma? Ochsner J. 10, 193-199 (2010
-
(2010)
Ochsner J.
, vol.10
, pp. 193-199
-
-
Risberg, K.1
Fodstad, O.2
Andersson, Y.3
-
112
-
-
33646267674
-
Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong
-
Chan, K. H. et al. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J. Gastroenterol. 12, 2223-2228 (2006
-
(2006)
World J. Gastroenterol
, vol.12
, pp. 2223-2228
-
-
Chan, K.H.1
-
113
-
-
60149099021
-
Cluster of Hodgkin's lymphoma in residents near a nonoperational petroleum refinery
-
Dahlgren, J., Klein, J. & Takhar, H. Cluster of Hodgkin's lymphoma in residents near a nonoperational petroleum refinery. Toxicol. Ind. Health 24, 683-692 (2008
-
(2008)
Toxicol. Ind. Health
, vol.24
, pp. 683-692
-
-
Dahlgren, J.1
Klein, J.2
Takhar, H.3
-
114
-
-
79954442549
-
Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia
-
Helbig, G. et al. Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia. Cancer Chemother. Pharmacol. 67, 967-969 (2011
-
(2011)
Cancer Chemother. Pharmacol
, vol.67
, pp. 967-969
-
-
Helbig, G.1
-
115
-
-
84868199576
-
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
-
Deshpande, H., Marler, V. & Sosa, J. A. Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer. Onco. Targets Ther. 4, 209-215 (2011
-
(2011)
Onco. Targets Ther
, vol.4
, pp. 209-215
-
-
Deshpande, H.1
Marler, V.2
Sosa, J.A.3
-
116
-
-
80054106619
-
Janus kinase inhibitors: An update on the progress and promise of targeted therapy in the myeloproliferative neoplasms
-
Stein, B. L., Crispino, J. D. & Moliterno, A. R. Janus kinase inhibitors: An update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr. Opin. Oncol. 23, 609-616 (2011
-
(2011)
Curr. Opin. Oncol
, vol.23
, pp. 609-616
-
-
Stein, B.L.1
Crispino, J.D.2
Moliterno, A.R.3
-
117
-
-
18144392678
-
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma
-
Vidal, M., Wells, S., Ryan, A. & Cagan, R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 65, 3538-3541 (2005
-
(2005)
Cancer Res
, vol.65
, pp. 3538-3541
-
-
Vidal, M.1
Wells, S.2
Ryan, A.3
Cagan, R.4
-
118
-
-
48749101265
-
Germline and somatic c met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients
-
Salvi, A. et al. Germline and somatic c met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int. J. Oncol. 33, 271-276 (2008
-
(2008)
Int. J. Oncol
, vol.33
, pp. 271-276
-
-
Salvi, A.1
-
119
-
-
33645687784
-
Dasatinib (BMS 354825) inhibits KITD816V, an imatinib resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
-
Shah, N. P. et al. Dasatinib (BMS 354825) inhibits KITD816V, an imatinib resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108, 286-291 (2006
-
(2006)
Blood
, vol.108
, pp. 286-291
-
-
Shah, N.P.1
-
120
-
-
0030738403
-
All-trans retinoic acid significantly increases 5 year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
-
Soignet S., Fleischauer, A., Polyak, T., Heller, G. & Warrell, R. P. Jr. All-trans retinoic acid significantly increases 5 year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study. Cancer Chemother. Pharmacol. 40 (Suppl.), S25-S29 (1997
-
(1997)
Cancer Chemother. Pharmacol
, vol.40 SUPPL.
-
-
Soignet, S.1
Fleischauer, A.2
Polyak, T.3
Heller, G.4
Warrell Jr., R.P.5
-
121
-
-
0000492653
-
All trans retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia
-
Adamson, P. C. All trans retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia. Oncologist 1, 305-314 (1996
-
(1996)
Oncologist
, vol.1
, pp. 305-314
-
-
Adamson, P.C.1
-
122
-
-
84860382327
-
The role of BRAF V600 mutation in melanoma
-
Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012
-
(2012)
J. Transl. Med
, vol.10
, Issue.85
-
-
Ascierto, P.A.1
-
123
-
-
84866749554
-
Gastrointestinal stromal tumors (GIST): A rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes
-
Blay, J. Y., Le Cesne, A., Cassier, P. A. & Ray-Coquard, I. L. Gastrointestinal stromal tumors (GIST): A rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov. Med. 13, 357-367 (2012
-
(2012)
Discov. Med
, vol.13
, pp. 357-367
-
-
Blay, J.Y.1
Le Cesne, A.2
Cassier, P.A.3
Ray-Coquard, I.L.4
-
124
-
-
84863676500
-
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
-
Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30, 2183-2189 (2012
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 2183-2189
-
-
Younes, A.1
|